Dopamine and Glutamate Receptor Assay Service

Creative Biolabs offers comprehensive, high-precision, multi-dimensional dopamine (DA) and glutamate (Glu) receptor assay services, backed by extensive neurobiology research, to support investigations into neurodegenerative disorders, mental illnesses, and pharmaceutical development. For further information regarding the products and services provided, project-specific consultation, and pricing, please submit an inquiry here.

Advanced Receptor Detection Platform

• Fluorescent Biosensors

Real-time monitoring of cAMP fluctuations, enabling precise quantification of receptor activation and inhibition (e.g., D1R/D5R activation-induced fluorescence enhancement, D2R/D4R inhibition-driven fluorescence reduction).

• Interaction and Colocalization Analysis

Utilizing Co-IP and bioluminescence technology to elucidate physical interactions between DA receptors (e.g., D1R) and NMDA receptors (NR1), revealing their coordinated signaling pathway regulation at the postsynaptic membrane.

• Comprehensive Supporting Methodologies

Including ELISA and Western Blot (WB) for receptor expression level analysis and single nanoparticle imaging for dynamic synaptic receptor distribution.

Comprehensive Coverage of Multiple Receptor Subtypes

• Dopamine Receptor Testing

• Glutamate Receptor Testing

Case Study: GluN1-D1R interaction is increased in immature neurons.

Fig.1 Using a co-immunoprecipitation assay with validated GluN2A subunit antibodies, we quantified in vivo D1R-NMDAR complex levels. Our results showed a twofold increase in these complexes within the adult rat hippocampus compared to postnatal day 8 (P8) animals, indicating a significant developmental upregulation of D1R-NMDAR interactions.¹

Applications

Neurodegenerative Disease Research	Psychiatric Disease Research
We analyze the impact of dopamine (DA) deficiency on NMDA receptor subunit (NR2A/NR2B) tyrosine phosphorylation, including changes in receptor subcellular localization and the efficacy of drug interventions.	Our platform supports efficacy screening of targeted D3 receptor antagonists or NMDA enhancers, addressing DA-D3 receptor overactivation and NMDA receptor dysfunction.

Explore the complex interaction network of dopamine and glutamate receptors to accelerate your research on the mechanism of neurological diseases or innovative drug development. For more information, please visit our website or contact us to discuss a customized plan and quote.

Reference

1. Bénac, Nathan, et al. "Non-canonical interplay between glutamatergic NMDA and dopamine receptors shapes synaptogenesis." Nature Communications 15.1 (2024): 27. Distributed under Open Access license CC BY 4.0, without modification.